乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

WCLC

<乌鸦传媒>New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC

Overall survival benefit now demonstrated

<乌鸦传媒>Low-Dose Sotorasib 'Lead-in' Strategy Promising in NSCLC Subset

Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option

<乌鸦传媒>Sublobar Resection the 'New Standard of Care' in Small-Sized NSCLC?

Large randomized study shows non-inferiority to lobectomy

<乌鸦传媒>Young Adults With NSCLC More Apt to Get Advanced Disease Diagnosis

Study finds minimal improvements in the early diagnosis of young patients with lung cancer

<乌鸦传媒>More Help on the Way for Lung Cancers With Exon 20 Mutations?

Early trials of DZD9008 demonstrated responses in over a third of patients

<乌鸦传媒>Cancer Vaccine May Boost Anti-EGFR Efficacy in Non-Small Cell Lung Cancer

More than 90% disease control rate, hint of improved PFS in pilot trial

<乌鸦传媒>Novel ADC Promising in Certain Non-Squamous Lung Cancers

Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression

<乌鸦传媒>More Data in Support of Surgery for Malignant Pleural Mesothelioma

Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone

<乌鸦传媒>Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancer

LDCT associated with a 16% relative reduction in mortality versus no screening

<乌鸦传媒>Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC

Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer

<乌鸦传媒>Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesothelioma

Atezolizumab add-on offers promising outcomes in phase I trial

<乌鸦传媒>Durable Response with Immunotherapy Combos in NSCLC with Brain Metastases

Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease

<乌鸦传媒>Dual Immunotherapy Boosts Survival in Metastatic NSCLC

Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology

<乌鸦传媒>Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patients

Patients often did not consult with radiation or medical oncologists

<乌鸦传媒>Second-Line Combo Fails to Improve Survival in SCLC

No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options

<乌鸦传媒>High Response Rate in Non-Small Cell Lung Cancer With RET Inhibitor

Responses in 66-80% of patients from China confirm activity of pralsetinib

<乌鸦传媒>TROP2 Antibody-Drug Conjugate Shows Promise in Lung Cancer

Disease control observed in over two-thirds of patients at selected dose

<乌鸦传媒>KRAS Inhibitor Continues to Impress in NSCLC

Sotorasib yielded deep and durable responses in over one-third of patients

<乌鸦传媒>Nab-Paclitaxel as Possible Option for Relapsed NSCLC

Noninferior to docetaxel for OS, though impact on clinical practice questioned

<乌鸦传媒>Promising Data for Preop Checkpoint Inhibition in NSCLC

Major response rate of 21%, encouraging survival with single-agent atezolizumab

<乌鸦传媒>First-Ever Survival Bump in Relapsed Mesothelioma

OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers

<乌鸦传媒>Dual Checkpoint Blockade No Help in PD-L1-High NSCLC

Single-agent pembrolizumab wins out as first-line therapy for advanced disease

<乌鸦传媒>COVID Affects Cancer Care, Patients' Mental Health

Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients

<乌鸦传媒>Chemo-Free Regimen Boosts OS in Mesothelioma

Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo

<乌鸦传媒>Another ALK Drug Tops Crizotinib in First-Line NSCLC

Ensartinib doubled PFS over older standard, with improved CNS activity

<乌鸦传媒>Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Word

Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure"

<乌鸦传媒>'Dirtier' Drugs Step Aside in RET-Positive NSCLC

Over two-thirds of patients respond to selective RET inhibitor

<乌鸦传媒>TMB in Lung Cancer: 'Not Ready for Prime Time'

No association between tumor mutational burden and outcomes in three trials

<乌鸦传媒>More Evidence that Screening Cuts Lung Cancer Deaths

Significantly lower risk in men and women

<乌鸦传媒>Newer ALK Inhibitor Tops Standard in NSCLC

Significant improvement in PFS with brigatinib after short follow-up

<乌鸦传媒>Anti-PD-L1 Drug Boosts Survival in Stage III NSCLC

New standard of care for patients with inoperable disease

<乌鸦传媒>Add-On Keytruda Boosts OS in Advanced Squamous Lung Cancer

Benefit seen across all subgroups, PD-L1 expression levels

<乌鸦传媒>No Survival Benefit with Cranial RT for NSCLC

Better disease-free survival, fewer brain mets